STOCK TITAN

Alcon Inc. - ALC STOCK NEWS

Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.

Alcon Inc. Ordinary Shares (symbol: ALC) is a premier American-Swiss healthcare company headquartered in Geneva, Switzerland, and incorporated in Fribourg, Switzerland. Renowned globally for its eye care products, Alcon excels in vision care and surgical segments, making it a leader in the eye care industry. Having spun off from Novartis in April 2019, Alcon now independently operates to enhance the quality of life through innovative vision products.

Alcon’s vision care segment includes a wide range of products such as contact lenses, lens care solutions, and ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon boasts significant control over the U.S. contact lens market. Their surgical segment offers advanced solutions like intraocular lenses (IOLs), ophthalmic surgical equipment, and consumables used during surgeries. Notable products include the Centurion phacoemulsification device and the Clareon, PanOptix, and Vivity IOLs.

Recently, Alcon launched the Clareon Vivity, which is the world’s first non-diffractive extended depth of focus (EDOF) intraocular lens. This innovative IOL incorporates wavefront-shaping technology, offering superior visual outcomes for cataract patients seeking presbyopia correction. The Clareon platform enhances Alcon's portfolio, which already includes the highly successful PanOptix lenses.

Financially, Alcon has shown robust growth. For Q4 2023, Alcon's sales reached $2.3 billion, marking an 8% increase from the previous year. Diluted EPS was $0.86, reflecting a 78% increase, and core diluted EPS was $0.70, up 67%. Alcon also reported a strong cash flow, with $937 million generated from operating activities in the first nine months of 2023.

Alcon's dedication to innovation and quality in eye care is further evidenced by its extensive research and development initiatives. The company engages in partnerships with eye care professionals and offers educational resources through the Alcon Experience Academy. Through consistent advancements and a customer-centric approach, Alcon continues to lead in enhancing sight and improving lives globally.

Rhea-AI Summary

Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received U.S. FDA 510(k) clearance. These systems are the first innovations from Alcon's Unity portfolio, aimed at transforming surgical procedures in ophthalmology. Alcon plans to gather real-world user feedback in the U.S. before a broad commercialization in 2025. The Unity systems are set to replace Alcon's current leading systems and introduce significant workflow efficiencies. Regulatory submissions will continue globally, with a CE Mark expected in early 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary

Alcon reported strong first-quarter 2024 financial results, with sales reaching $2.4 billion, a 5% increase (7% constant currency). Diluted EPS rose 43% to $0.50, while core diluted EPS improved by 11% to $0.78. The company saw significant growth in its Surgical and Vision Care segments, particularly in innovative contact lenses, which achieved record sales. Operating income rose to $368 million, with a 15.1% operating margin. Cash from operations jumped to $341 million, with free cash flow at $229 million, a $248 million year-over-year increase. A dividend of CHF 0.24 per share was approved. The company's 2024 outlook remains optimistic, maintaining sales and core EPS guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.33%
Tags
-
Rhea-AI Summary

Alcon Inc. announced the successful approval of all proposed resolutions at its 2024 Annual General Meeting. This includes the approval of a dividend of CHF 0.24 per share, re-election of F. Michael Ball as Chair of the Board of Directors, approval of the Board and Executive Committee compensation, and acceptance of financial reports. Shareholders also re-elected other members of the Board and committees, granted discharge to Board and Executive Committee members, and re-elected auditors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
Rhea-AI Summary
Alcon (ALC) announces its second in-person Annual General Meeting (AGM) with a proposed dividend of CHF 0.24 cash per share. Shareholders will vote on the Report on Non-Financial Matters, among other agenda items. The AGM will take place on May 8, 2024, with important dates for dividend payment outlined.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary
Alcon launches Clareon Family of intraocular lenses in India, offering exceptional clarity and predictable refractive outcomes. The new IOL material has low levels of haze and nanoglistenings, setting it apart from competitors. The Clareon platform includes PanOptix and Vivity technologies, with high patient satisfaction rates. Alcon aims to revolutionize cataract surgery with innovative IOL technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
Rhea-AI Summary
Alcon celebrates surpassing one million implants of AcrySof IQ Vivity and Clareon Vivity extended depth of focus intraocular lenses globally. Vivity, with its patented wavefront-shaping technology, offers excellent outcomes for cataract patients, addressing presbyopia and expanding patient candidacy pool.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
Rhea-AI Summary
Alcon (ALC) reported strong financial results for Q4 2023, with sales of $2.3 billion, up 8% or 10% constant currency, and diluted EPS of $0.86. FY 2023 sales were $9.4 billion, up 8%, and diluted EPS was $1.96. The company projects 6-8% sales growth and 13-16% core diluted EPS growth for FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
Alcon has launched TOTAL30 Multifocal, the first monthly Water Gradient multifocal contact lens that provides excellent visual acuity at all distances, addressing the needs of the growing global multifocal market. The lens helps outsmart digital device dryness and presbyopia, which affects nearly 80% of people aged 45-55. The company aims to offer premium Water Gradient innovation at an accessible price point, with a proven fit success rate of 96%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Summary
Alcon (ALC) announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both trials, the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score achieved statistical significance at Day 14 [p<0.0001]. Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product. AR-15512 has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
Rhea-AI Summary
Alcon (ALC) CEO David Endicott to Present at 2024 J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences

FAQ

What does Alcon Inc. specialize in?

Alcon Inc. specializes in eye care products, including contact lenses, lens care solutions, ocular health products, intraocular lenses (IOLs), and ophthalmic surgical equipment.

When did Alcon become an independent company?

Alcon became an independent public company in April 2019, following its spin-off from Novartis.

What are Alcon’s major product brands in the vision care segment?

Major product brands in Alcon’s vision care segment include Dailies, Total1, and Air Optix.

What significant recent product has Alcon launched?

Alcon recently launched the Clareon Vivity, the first non-diffractive extended depth of focus (EDOF) intraocular lens, incorporating wavefront-shaping technology.

How did Alcon perform financially in Q4 2023?

In Q4 2023, Alcon reported sales of $2.3 billion, an 8% increase from the previous year, with a diluted EPS of $0.86 and a core diluted EPS of $0.70.

What educational resources does Alcon offer?

Alcon offers educational resources through the Alcon Experience Academy, providing training and education for eye care professionals and supporting staff.

Where is Alcon Inc. headquartered?

Alcon Inc. is headquartered in Geneva, Switzerland and incorporated in Fribourg, Switzerland.

What segments does Alcon operate in?

Alcon operates in two main segments: vision care and surgical.

How has Alcon shown its commitment to innovation?

Alcon shows its commitment to innovation through continuous research and development, launching cutting-edge products like Clareon Vivity IOL, and partnerships with eye care professionals.

Who are the primary beneficiaries of Alcon's products?

The primary beneficiaries of Alcon's products are individuals with eye conditions such as cataracts, glaucoma, retinal diseases, and refractive errors, along with eye care professionals.

Alcon Inc.

NYSE:ALC

ALC Rankings

ALC Stock Data

44.40B
494.40M
0.14%
73.07%
0.84%
Ophthalmic Goods Manufacturing
Manufacturing
Link
United States of America
Vernier